RVMD

Over the past six months, Revolution Medicines' stock has shown significant movement, with a 52-week range between $42.18 and $224.31 and a substantial 331.73% increase over the last year. Recent events include Goldman Sachs reinitiating coverage with a 'Buy' rating and a $267 price target on September 24, 2026. On September 22, 2026, the FDA granted Breakthrough Therapy Designation to RASONQUE for treatment-naïve metastatic pancreatic adenocarcinoma, and the company was added to the FTSE All World Index. The company received FDA Breakthrough Designation for cancer treatment on September 14, 2026. Insider Stephen Kelsey sold 92,531 shares for approximately $18.7 million on September 11, 2026. Revolution Medicines was added to the Bloomberg 500 (B500) Index on August 26, 2026. In August 2026, the company reported a quarterly loss of $3.06 per share, missing consensus estimates. The European Medicines Agency's CHMP began a phased review of daraxonrasib on July 16, 2026. Shares experienced a premarket slide on May 1, 2026, following reports of cooling talks with Merck. In May 2026, the FDA permitted expanded access to daraxonrasib for eligible patients. Pivotal Phase III trial results for daraxonrasib in April 2026 demonstrated significant improvement in median overall survival for patients with previously treated metastatic pancreatic cancer. The stock gained on January 26, 2026, due to reports of a possible acquisition by AbbVie, and rose on January 7, 2026, after the FDA granted priority designation for a cancer treatment. CEO Mark Goldsmith also sold a substantial amount of stock in September 2026.